Edwards Lifesciences (EW) Accumulated Depreciation & Amortization (2009 - 2025)

Edwards Lifesciences has reported Accumulated Depreciation & Amortization for 14 years, with the latest figure at $156.6 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 0.9% year-over-year to $156.6 million; the trailing twelve-month figure through Dec 2025 stood at $156.6 million (up 0.9% YoY), and the FY2025 full-year result was $156.6 million, up 0.9% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $156.6 million, up from $155.2 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $156.6 million in Q4 2025, with the low at $139.6 million in Q4 2022.
• Average Accumulated Depreciation & Amortization over 4 years is $149.1 million, with a median of $150.0 million recorded in 2023.
• Year-over-year, Accumulated Depreciation & Amortization increased 7.11% in 2024 and increased 0.9% in 2025.
• Tracing EW's Accumulated Depreciation & Amortization over 4 years: stood at $139.6 million in 2022, then grew by 3.8% to $144.9 million in 2023, then advanced by 7.11% to $155.2 million in 2024, then increased by 0.9% to $156.6 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $156.6 million (Q4 2025), $155.2 million (Q4 2024), and $144.9 million (Q4 2023), per Business Quant data.

Peer Comparison